Gut microbiota-mediated hsa_circ_0126925 targets BCAA metabolic enzyme BCAT2 to exacerbate colorectal cancer progression
- Mol Cancer Res. 2024 Dec 6. doi: 10.1158/1541-7786.MCR-24-0434.
- 1. First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- 2. Soochow University, Suzhou, Jiangsu, China.
- 3. Zhongnan Hospital of Wuhan University, Suzhou, Jiangsu, China.
- 4. Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu, China.
- 5. The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- 6. Medical College of Soochow University, Suzhou, Jiangsu, China.
- 7. First Affiliated Hospital of Soochow University, Suzhou, China.
- 8. Soochow University Medical College, Suzhou, China.
Recent evidence indicates that a high-fat diet (HFD) can promote tumor development, especially colorectal Cancer (CRC), by influencing the microbiota. Regulatory circular RNAs (circRNAs) play an important role in modulating host-microbe interactions; however, the specific mechanisms by which circRNAs influence Cancer progression by regulating these interactions remain unclear. Here, we report that consumption of a HFD modulates the microbiota by specifically upregulating the expression of the noncoding RNA hsa_circ_0126925 (herein referred to as circ_0126925) in CRC. Acting as a scaffold, circ_0126925 hinders the recruitment of the E3 ubiquitin Ligase tripartite motif-containing protein 21 (TRIM21) to branched-chain amino acid transaminase 2 (BCAT2), leading to reduced degradation of BCAT2. This reduction in targeted degradation of BCAT2 can protect tumours from limited branched-chain Amino acids (BCAAs) interference by improving the metabolism of BCAAs in CRC. Taken together, these data demonstrate that circ_0126925 plays a critical role in promoting the progression of CRC by maintaining BCAA metabolism and provide insight into the functions and crosstalk of circ_0126925 in host-microbe interactions in CRC. Implications: This study preliminarily confirms that circRNAs do indeed respond to microbiota/microbial metabolites, providing further evidence for the potential development of circRNAs as diagnostic tools and/or therapeutic agents to alleviate microbiome related pathology in humans.